Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Patent
1994-11-07
1996-04-02
Woodward, Michael P.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
4241841, 4241851, 4241901, 4242011, 4242531, 4242541, 4242341, 435 693, 514 2, 530350, 530825, 536 237, 536 234, A61K 3910, A61K 39295, C07K 14235, C07K 1700
Patent
active
055038298
ABSTRACT:
A recombinant plasmid comprises the cyaC and the cyaA genes of Bordetella which directs the expression of Bordetella, adenylate cyclase in a transformed host cell. A recombinant DNA molecule can comprise the Bordetella cyaA gene containing at least one insertion of a heterologous DNA sequence at at least one permissive site. In addition, a recombinant Bordetella adenylate cyclase comprises a heterologous epitope at a permissive site. Methods of inducing a specific B cell, helper T cell, and CTL cell immune response are provided.
REFERENCES:
patent: 5183745 (1993-02-01), Dancain et al.
Goyard et al., Bordetella pertussis Adenylate Cyclase: A Toxin with Multiple Talents, Zbl. Bakt. 278, 326-333 (1993).
Epitopes of HIV and SIV. I. Host Responses, AIDS Res Human Retroviruses, 7(2):144-147 (1991). Entire Section, pp. 144-147!.
Aichele et al., Antiviral Cytotoxic T Cell Response Induced by In Vivo Priming with a Free Synthetic Peptide, J. Exp. Med., 171(5):1815-20 (1990).
Leclerc et al., J. Immunol., 147:3542-3552 (1991).
Fayolle et al., J. Immunol., 147:4069-4073 (1991).
Leclerc et al., J. Virol., 65:711-718 (1991).
Sebo et al., Gene, 104:19-24 (1991).
Ladant et al., J. Biol. Chem., 267(4):2244-2250 (1992).
Vaccine, vol. 10, p. 638 (1992).
Tam, J. P. et al. Proc. Natl. Acad. Sci USA 86:9084-9088, 1989.
Cossell, D. et al. Ann. N. Y. Acad. Sci, 51-60, 1991.
Glasu, P. et al. EMBO Journal 8(3):967-72 (1989).
Hanshi, E. et al. TIBS 14:459-463 (1989).
Moore, M. et al. Cell 54:777-785 (1988).
Schulz, M. et al. Eur. J. Inumunol. 19: 1657-1667.
Ladant Daniel
Leclerc Claude
Sebo Peter
Ullmann Agnes
Institut Pasteur
Tuscan Michael S.
Woodward Michael P.
LandOfFree
Recombinant mutants for inducing specific immune responses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant mutants for inducing specific immune responses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant mutants for inducing specific immune responses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2014857